<dd id="oxrwu"><optgroup id="oxrwu"></optgroup></dd>

    1. <s id="oxrwu"><object id="oxrwu"></object></s>
      <th id="oxrwu"><pre id="oxrwu"><rt id="oxrwu"></rt></pre></th>
      <dd id="oxrwu"><noscript id="oxrwu"></noscript></dd>
      1. <em id="oxrwu"><object id="oxrwu"></object></em>
      2. <tbody id="oxrwu"></tbody>

        <button id="oxrwu"><acronym id="oxrwu"></acronym></button>
      3. RNA合成藥物


        RNAi technology refers to highly conserved, double-stranded RNA induced, highly specific degradation of homologous mrnas in the evolutionary process, and is a post-transcriptional gene silencing (PTGS) that degrades mrnas.

        The main mechanism of RNAi is that long double RNA is cleaved into short RNA and binds with protein to form siRNA-induced interference complex (RISC). After the degradation of the righteous strand of short RNA, RISC binds to specific mRNA to degrade the mRNA and eventually silences the expression of specific genes.

        Known RNAi mainly include siRNA, miRNA and piRNA.


        ASO refers to a single strand of DNA or RNA sequence that is complementary to the mRNA of the target gene, usually consisting of a dozen to dozens of bases and produced by chemical synthesis.

        After some specific chemical modifications of ASO, ASO drugs enter cells in a certain way and can specifically regulate the expression of target genes.


        For the treatment of rare or refractory sexually transmitted diseases, cancer and genetic diseases at the genetic level.?ASO and RNAi therapy are similar in principle, both of which aim to degrade or inhibit sequentially complementary target mRNAs to achieve expression silencing of related genes.
        The Previous: miRNA測序